A case of severe reversible lung disease caused by sulphasalazine

International Journal of Clinical Practice

Volumn 53, Issue 3, 1999, Pages 233-235

  Manchanda, S ^a   Rees, P J ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; SALAZOSULFAPYRIDINE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ALVEOLITIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

AGED; GASTROINTESTINAL AGENTS; HUMANS; LUNG DISEASES; MALE; SULFASALAZINE;

EID: 0032951812     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Averbuch M, Halpern Z, Hallak A et al. Sulphasalazine pneumonitis. Am J Gastroenterol 1985; 80(5): 343-345.
2. Anonymous. Case records of the Massachusetts General Hospital. Weekly clinicopathological exericses. Case 12-1993: a 44-year-old man with pulmonary disease and produis. N Engl J Med 1993; 328(12): 869-876.
3. Constantinides K. Eosinophilic pneumonia: an unusual side effect of therapy with salicylazosulfapyridine. Chest 1976; 70(2): 315-316.
4. Abdulgany Hamadeh M, Atkinson J, Smith LJ. Sulphasalazine induced pulmonary disease. Chest 1992; 101(4): 1033-1037.
5. Boyd O, Gibbs AR, Smith AP. Fibrosing alveolitis due to sulphasalazine in apatient with rheumatoid arthritis. Br J Rheum 1990; 29(3): 222-224.
6. Jones GR, Malone DNS. Sulphasalazine induced lung disease. Thorax 1972; 27: 713-717.
7. Davies D, MacFarlane A. Fibrosing alveolitis and treatment with sulphasalazine. Gut 1974; 15: 185-188.
8. Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans and sulfasalazine therapy. Chest 1982; 6: 766-768.
9. Camus P, Piard F, Ashcroft T et al. The lung in inflammatory bowel disease. Medicine 1993; 72(3): 151-183.